Research on relation between genotype and effect of lamivudine in patient with hepatitis B virus infection

Abstract

Abstract: AIM: To investigate the relation between the genotype and the effect of lamivudine in patient with hepatitis B virus infection.METHODS: The genotype of hepatitis B virus and the YMDD mutation of 41 chronic hepatitis B patients with lamivudine treatment were detected and analyzed by DNA sequencing and oligochip technology. The DNA of HBV and the levels of ALT were detected before therapy and after 3, 6, 9, and 12 months with lamivudine treatment.RESULTS: 21 samples were classified as genotype B (51. 2 %) and 20 as genotype C (48. 8 %) in 41 samples. There were no significant differences on the levels of ALT between genotype B and C before and after lamivudine treatment for 12months (P > 0. 05). After lamivudine treatment, the rate of the transform negative of HBV DNA in genotype C was significantly higher than that in genotype B, and the rate of the bounce of HBV DNA in genotype B was higher than that in genotype C (P<0. 01). There were no significant difference on the rate of mutation in YMDD betmeen genotype B and C (P >0. 05).CONCLUSION: There may be a relation between the effect of lamivudine and the genotype of Hepatitis B virus.The effect of the lamivudine treatment may be better in the patients with genotype C.

Key words: hepatitis B virus, genotype, lamivudine, efficacy, genotype

CLC Number:

R978.7

ZHANG Hong-He, SHAO Ting-Jun, YANG Zhong-Guo. Research on relation between genotype and effect of lamivudine in patient with hepatitis B virus infection[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9): 1050-1053.

References

1 Okamoto H, Tsuda F, Sakugawa H.Typing hepatitis B virus by homology in nucleotide sequence: comparison of surfase subtype [J]. J Gen Virol, 1988;69(10): 2575-83
2 Norder H, Courouce AM, Magnius LO.Complete genomes phylogenetic relatedness and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes [J]. Virology, 1994; 198(2): 489-503
3 Stuyver L, De GS, Van GC, Zoulim F, Fried M, Schinazi RF. A new genotype of hepatitis B virus:complete genome and phylogenetic relatedness[J]. J Gen Virol, 2000;81(1): 167-74
4 Arauz RP, Norder H, Robertson BH, Magnius LO.Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America[J]. J Gen Virol, 2002; 83(8): 2059-73
5 Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients[J]. Gastroenterology, 2002; 123(6): 1848-56
6 Wai CT, Chu CJ, HussainM, Lok AS. HBV genotype B is associated with better response to interferon therapy in HbeAg(+) chronic hepatitis than genotype C[J]. Hepatology, 2002; 36 (6): 1425-30
7 Chayama K, Suzuki Y, Kobayashi M. Emergence and takeover of YMDD motif mutant Hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy[J]. Hepatology, 1998; 27(6): 1711-6
8 Lau DT, Khokhar MF, Doo E.Long-term therapy of chronic Hepatitis B with lamivudine[J]. Hepatology, 2000;32(4): 828-34
9 Bartholomew MM, Jansen RW, Jeffers LJ. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation[J]. Lancet, 1997;349(1): 20-2
10 Honkoop P, Niesters HG, deMan RA, Osterhaus AD, Schalm SW.Lamivudine resistance in immunocompetent chronic hepatitis B incidence and patterns[J]. J Hepatol, 1997;26(6): 1393-5
11 LindhM, Andersson AS, Gusdal A.Genotypes, NT 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method[J]. J Infect Dis, 1997;175(6): 1285-93
12 Norder H, Hammas B, Lee SD.Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen[J]. J Gen Virol, 1993;74(7): 1341-8
13 Norder H, Hammas B, Lofdahl S, Courouce AM, Magnius LO.Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains[J]. J Gen Virol, 1992;73(5): 1201-8
14 Allen MI, Deslauriers M, Andrews CW.Identification and characterization of mutations in hepatitis B virus resistant to lamivudine[J]. Hepatology, 1998;27(6): 1670-7
15 Norder H, Courouce AM, Magnius LO.Molecular basis of hepatitis B virus serotype variations within the four major subtypes[J]. J Gen Virol, 1992;73(12): 3141-5

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[3]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[4]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[5]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[6]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[7]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[8]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[9]	TAO Chengjing, LIU Shourong, CHENG Xiaoxian, HU Jiannv, BAI Xiuli, ZHANG Suying, ZHAO Chun, ZUO Zhongbao. Effects of different postpartum withdrawal time of tenofovir on hepatitis B virus markers, virology and biochemical indexes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1146-1152.
[10]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[11]	SHI Lili, LIU Xingan, SHAN Guoyong. Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
[12]	WAN Ping, LIU Liang, ZHANG Ping, ZHANG Zhongdong. Influential factors of serum concentration/dosage ratio for schizophrenia patients after oral administration of olanzapine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1024-1029.
[13]	YIN Ziyi, WANG Feng, ZHAO Meng, ZHANG Tie, WANG Pilin. Effects of thymidine phosphorylase genetic variation on the prognosis of Her2 negative metastatic breast cancer patients treated with capecitabine based first line chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1002-1008.
[14]	LIN Min, SHEN Zhongxia, QIAN Mincai, CUI Lijun, REN Lie, CAI Min, SHEN Xinhua. Relationship between 5-HTT gene polymorphism and treatment response in the treatment of generalized anxiety disorder patients with anti-depressants [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 903-909.
[15]	ZHU Songzhi. Therapeutic effect and related factors of human fibrinogen on traumatic traumatic coagulopathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 693-698.